■ CD19 モノクローナル抗体(品番:65110-1-Ig)

図1. CD19抗体とアイソタイプコントロール抗体を用いた細胞表面マーカー解析
1X10^6 human peripheral blood lymphocytes were surface stained with 0.5 ug Anti-Human CD19 (65110-1-Ig, Clone: HIB19) and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) at dilution 1:1000 (green), or stained with 0.5 ug isotype control and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) at dilution 1:1000 (black). Samples were not fixed.
■ CD19 モノクローナル抗体(品番:FITC-65110)

図1. CD19抗体とCD3抗体を用いた細胞表面マーカー解析
1X10^6 human peripheral blood lymphocytes were surface stained with APC Anti-Human CD3 (APC-65151, Clone: UCHT1) and 5.00 ul FITC Anti-Human CD19 (FITC-65110, Clone: HIB19). Cells were not fixed.
図2. アイソタイプコントロール抗体とCD3抗体を用いた細胞表面マーカー解析
1X10^6 human peripheral blood lymphocytes were surface stained with APC Anti-Human CD3 (APC-65151, Clone: UCHT1) and FITC-Mouse IgG1 isotype control. Cells were not fixed.
■ CD19 モノクローナル抗体(品番:PE-65110)

図1. CD19抗体とアイソタイプコントロール抗体を用いた細胞表面マーカー解析
1X10^6 human peripheral blood lymphocytes were surface stained with 0.25 ug PE-anti-human CD19 (PE-65110, clone HIB19) (red) or 0.25 ug PE-mouse IgG1 isotype control (blue). Samples were not fixed.
図2. CD19抗体とCD3抗体を用いた細胞表面マーカー解析
0.1 mL human whole blood cells were surface stained with 0.25 ug APC-anti-human CD3 (APC-65151, clone UCHT1) and 0.25 ug PE-anti-human CD19 (PE-65110, clone HIB19). Samples were then treated with red blood cell lysis buffer and were gated for lymphocytes for analysis of CD3 and CD19 staining. Samples were not fixed.
■ CD19 モノクローナル抗体(品番:APC-65110)

図1. CD19抗体とアイソタイプコントロール抗体を用いた細胞表面マーカー解析
1X10^6 human peripheral blood lymphocytes were surface stained with 0.125 ug APC-anti-human CD19 (APC-65110, clone HIB19) (red) or 0.125 ug APC-mouse IgG1 isotype control (blue). Samples were not fixed.
■ CD19 モノクローナル抗体(品番:CL488-65110)

図1. CD19抗体とCD3抗体を用いた細胞表面マーカー解析
1X10^6 human peripheral blood lymphocytes were surface stained with 5 ul CoraLite®647-conjugated Anti-Human CD3 (CL647-65151, Clone: UCHT1) and 5 ul CoraLite®488-conjugated Anti-Human CD19 (CL488-65110, Clone: HIB19). Cells were not fixed.
図2. アイソタイプコントロール抗体とCD3抗体を用いた細胞表面マーカー解析
1X10^6 human peripheral blood lymphocytes were surface stained with 5 ul CoraLite®647-conjugated Anti-Human CD3 (CL647-65151, Clone: UCHT1) and CoraLite®488-conjugated Mouse IgG1 isotype control. Cells were not fixed.
■ CD19 モノクローナル抗体(品番:CL594-65110)

図1. CD19抗体とCD3抗体を用いた細胞表面マーカー解析
1X10^6 human peripheral blood lymphocytes were surface stained with 5 ul CoraLite®647-conjugated Anti-Human CD3 (CL647-65151, Clone: UCHT1) and 5 ul CoraLite®594 Anti-Human CD19 (CL594-65110, Clone:HIB19). Cells were not fixed.
図2. アイソタイプコントロール抗体とCD3抗体を用いた細胞表面マーカー解析
1X10^6 human peripheral blood lymphocytes were surface stained with 5 ul CoraLite®647 Anti-Human CD3 (UCHT1) (CL647-65151, Clone: UCHT1) and CoraLite®594-conjugated Mouse IgG1 isotype control. Cells were not fixed.
■ CD19 モノクローナル抗体(品番:CL647-65110)

図1. CD19抗体とCD3抗体を用いた細胞表面マーカー解析
X10^6 human peripheral blood lymphocytes were surface stained with 5 ul CoraLite®488-conjugated Anti-Human CD3 (CL488-65151, Clone: UCHT1) and 5 ul CoraLite®647-conjugated Anti-Human CD19 (CL647-65110, Clone: HIB19). Cells were not fixed.
図2. アイソタイプコントロール抗体とCD3抗体を用いた細胞表面マーカー解析
1X10^6 human peripheral blood lymphocytes were surface stained with 5 ul CoraLite®488-conjugated Anti-Human CD3 (CL488-65151, Clone: UCHT1) and CoraLite®647-conjugated Mouse IgG1 isotype control. Cells were not fixed.